An Usher of Immunology Biosimilars in the Next 5 Years?
An Usher of Immunology Biosimilars in the Next 5 Years? Biosimilars are biologic medicines that are highly similar to existing licensed biologic products with no
An Usher of Immunology Biosimilars in the Next 5 Years? Biosimilars are biologic medicines that are highly similar to existing licensed biologic products with no
A Detailed Analysis of Patent Term Extensions Expiring in the U.S. between 2023-2028 A drug manufacturer can enjoy monopoly in the market till 20 years
Novo Nordisk’s RivflozaTM gets the U.S. FDA approval for treatment of primary hyperoxaluria type 1 (PH1) On 29th September, Novo Nordisk obtained approval from the U.S.
SPC manufacturing waiver to be amended in 2024? Pharmaceutical companies in the European Union (EU) are entitled to a sui generis form of protection for their approved
The Steepest Patent Cliff in Order Big pharma companies focusing on anti-diabetic drugs are bracing themselves for the steepest patent cliff this decade. With Eli
EU Pharmaceutical Legislation Reform to Enable Quicker Access and Foster Innovation In April 2023, the EU commission’s proposal to revise the pharmaceutical legislation consisted of
Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.
Copyright 2023 All right reserved by WSLI. Designed by Webpeckers.